WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) announced Tuesday its agreement
to acquire Escient Pharmaceuticals and its assets for $750 million plus its net
cash remaining at the deal closure, subject to customary adjustments.

The acquisition is subject to clearance under the Hart-Scott-Rodino Act, among
other customary conditions. The deal will become effective promptly following
the satisfaction or waiver of these conditions which is currently anticipated to
be by the third quarter of 2024.

Incyte said the acquisition will include EP262, a first-in-class, potent, highly
selective, once-daily small molecule antagonist of Mas-related G protein-coupled
receptor X2 or MRGPRX2, and EP547, a first-in-class oral MRGPRX4 antagonist.

Herve Hoppenot, Chief Executive Officer, Incyte, said, 'This acquisition builds
on our strategy to develop differentiated and first-in-class medicines with high
potential. EP262 and EP547 are complementary additions to our portfolio,
providing an opportunity to leverage our expertise, address the needs of
patients with inflammatory diseases and additional potential launch
opportunities starting in 2029.'

In the deal, Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient
and Fenwick & West LLP acted as legal counsel, while Covington & Burling LLP
acted as legal counsel for Incyte.

In pre-market activity on the Nasdaq, Incyte shares were gaining around 1.3
percent to trade at $52.60.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX